Mumbai-based pharma company Lupin Ltd has launched Liraglutide injection to help control blood sugar in the United States.
The injection, available in an 18 mg/3 mL single-patient prefilled pen, is used along with diet and exercise to improve blood sugar control in adults and children aged 10 years and above with type 2 diabetes.
The medicine is bioequivalent to Victoza® by Novo Nordisk, which has annual sales of around USD 350 million in the US.
Spiro Gavaris, President – US Generics at Lupin, said, “We are pleased to launch Liraglutide Injection in the US. This marks a significant milestone in enhancing our portfolio of complex injectables and highlights our continued commitment to making essential therapies more accessible for patients.”
In a separate development, Lupin said it has received USFDA approval for its Abbreviated New Drug Application (ANDA) for Rivaroxaban for Oral Suspension, 1 mg/mL. The product is bioequivalent to Xarelto® oral suspension of Janssen Pharmaceuticals and will be manufactured at Lupin’s Chhatrapati Sambhajinagar facility. It is indicated for the treatment of venous thromboembolism (VTE) and reduction of recurrent VTE risk in pediatric patients under 18, as well as for thromboprophylaxis in children aged two years and older with congenital heart disease after the Fontan procedure.
The company also announced last month that it has received tentative USFDA approval for its generic version of Biktarvy® tablets, used in the treatment of HIV infection. The generic version, containing bictegravir, emtricitabine, and tenofovir alafenamide (50 mg/200 mg/25 mg), will be manufactured at Lupin’s Nagpur facility. According to IQVIA MAT July 2025, Biktarvy had estimated annual US sales of USD 16.2 billion.
Shares of Lupin Ltd ended lower on Friday, October 3, by 0.32% at ₹1,975 on NSE.
